Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study

PF‐06817024 is a high affinity, humanized antibody that binds interleukin‐33, a proinflammatory type 2 cytokine, and thereby has the potential to inhibit downstream type 2 inflammation. This Phase 1, randomized, placebo‐controlled study was conducted in 3 parts to evaluate the safety, tolerability,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2024-05, Vol.64 (5), p.529-543
Hauptverfasser:	Danto, Spencer I., Tsamandouras, Nikolaos, Reddy, Padmalatha, Gilbert, Steven, Mancuso, Jessica, Page, Karen, Peeva, Elena, Vincent, Michael S., Beebe, Jean S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Allergic diseases Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacokinetics Antibodies, Monoclonal, Humanized - therapeutic use anti‐IL‐33 antibody Atopic dermatitis Chronic Disease chronic rhinosinusitis with nasal polyps Cytokines Dermatitis Dermatitis, Atopic - drug therapy Dose-Response Relationship, Drug Double-Blind Method Female healthy participants Healthy Volunteers Humans Immunogenicity Inflammation Interleukin-33 - blood Intravenous administration Male Middle Aged Nasal Polyps - drug therapy Pharmacodynamics Pharmacokinetics Phase 1 Placebos Polyps Population studies Rhinosinusitis Rhinosinusitis - drug therapy Safety Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!